Focus:
Janssen Pharmaceutical has received US Food and Drug Administration approval for the drug Balversa to treat adults with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.
Sanofi has said that it will reduce the cost of some of its insulin products to $99 per month in a bid to mitigate burden on diabetes patients in the...
Gene therapy company Asklepios BioPharmaceutical has received an investment of $225m from TPG Capital and Vida Ventures to accelerate its long-term growth.
Novartis unit Sandoz has entered an agreement to commercialise Japanese pharmaceutical company Shionogi’s drug Rizmoic (naldemedine) in the UK, Germany and the Netherlands.
The European Commission has approved AstraZeneca drug Lynparza as a monotherapy to treat locally-advanced or metastatic breast cancer in adults.
Pfizer has partnered with patient-centred research firm Concerto HealthAI to fast-track actionable patient insights for investigational and commercialised cancer therapies.
Regeneron Pharmaceuticals has formed an alliance with Alnylam Pharmaceuticals for the discovery, development and commercialisation of new RNA interference therapies.
Amgen has received the US Food and Drug Administration approval for Evenity to treat osteoporosis in postmenopausal women at high risk for fracture.
Researchers at Mount Sinai in the US have developed a new immunotherapy that can be injected directly into a tumour cell and teach a patient’s own immune system to kill...
Centene to fund Washington University’s personalised medicine research
